Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

2013—biotech back in the saddle

Last year's biotech stocks substantially outperformed the general markets, with the BioCentury 100 and NASDAQ Biotechnology indices showing >25% gains over the S&P 500 and NASDAQ Composite. Excluding partnership monies, a total of $36.7 billion was raised, on par with 2012. The first IPO window since 2007 brought in $3.8 billion, up 168% from 2012; follow-on offerings ($10 billion) were also up 58% from 2012; but debt deals were down from 2012's $19.6 billion. Private company fundraising came in at around the 2008–2012 annual average of $5.5 billion.

Stock market performance

Global biotech industry financing

Global biotechnology venture capital investment

Global biotech initial public offerings

Notable 2013 deals

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Yang, W. 2013—biotech back in the saddle. Nat Biotechnol 32, 126 (2014). https://doi.org/10.1038/nbt.2826

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.2826

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing